These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

873 related items for PubMed ID: 28418232

  • 1. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
    Hoagland B, Moreira RI, De Boni RB, Kallas EG, Madruga JV, Vasconcelos R, Goulart S, Torres TS, Marins LMS, Anderson PL, Luz PM, Costa Leite ID, Liu AY, Veloso VG, Grinsztejn B, PrEP Brasil Study TeamClinical Trial Number 01989611.
    J Int AIDS Soc; 2017 Apr 06; 20(1):21472. PubMed ID: 28418232
    [Abstract] [Full Text] [Related]

  • 2. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, Leite IC, Freitas L, Martins LMS, Torres TS, Vasconcelos R, De Boni RB, Anderson PL, Liu A, Luz PM, Veloso VG, PrEP Brasil Study Team.
    Lancet HIV; 2018 Mar 06; 5(3):e136-e145. PubMed ID: 29467098
    [Abstract] [Full Text] [Related]

  • 3. "I wish to remain HIV negative": Pre-exposure prophylaxis adherence and persistence in transgender women and men who have sex with men in coastal Kenya.
    Kimani M, van der Elst EM, Chirro O, Wahome E, Ibrahim F, Mukuria N, de Wit TFR, Graham SM, Operario D, Sanders EJ.
    PLoS One; 2021 Mar 06; 16(1):e0244226. PubMed ID: 33465090
    [Abstract] [Full Text] [Related]

  • 4. Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study.
    Marins LMS, Torres TS, Leite IDC, Moreira RI, Luz PM, Hoagland B, Kallas EG, Madruga JV, Liu AY, Anderson PL, Grinsztejn B, Veloso VG.
    PLoS One; 2019 Mar 06; 14(8):e0221281. PubMed ID: 31430318
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with men.
    van den Elshout MA, Hoornenborg E, Coyer L, Anderson PL, Davidovich U, de Vries HJ, Prins M, Schim van der Loeff MF, of the Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Initiative (H-TEAM).
    Sex Transm Infect; 2023 Aug 06; 99(5):303-310. PubMed ID: 37258273
    [Abstract] [Full Text] [Related]

  • 8. Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP.
    Jongen VW, Hoornenborg E, van den Elshout MA, Boyd A, Zimmermann HM, Coyer L, Davidovich U, Anderson PL, de Vries HJ, Prins M, Schim van der Loeff MF, Amsterdam PrEP Project team in the HIV Transmission Elimination Amsterdam (H-TEAM) Initiative.
    J Int AIDS Soc; 2021 May 06; 24(5):e25708. PubMed ID: 33973373
    [Abstract] [Full Text] [Related]

  • 9. Travestis, transgender women and young MSM are at high risk for PrEP early loss to follow-up in Rio de Janeiro, Brazil.
    Echeverría-Guevara A, Coelho LE, Veloso VG, Pimenta MC, Hoagland B, Moreira RI, Leite I, Jalil EM, Cardoso SW, Torres TS, Grinsztejn B.
    Braz J Infect Dis; 2023 May 06; 27(1):102733. PubMed ID: 36586721
    [Abstract] [Full Text] [Related]

  • 10. Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam.
    Hoornenborg E, Achterbergh RC, van der Loeff MFS, Davidovich U, van der Helm JJ, Hogewoning A, van Duijnhoven YT, Sonder GJ, de Vries HJ, Prins M, Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Initiative.
    J Int AIDS Soc; 2018 Mar 06; 21(3):e25105. PubMed ID: 29603900
    [Abstract] [Full Text] [Related]

  • 11. Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review.
    Wu L, Niu X, Brunelli MK, Mugwanya KK.
    Curr HIV/AIDS Rep; 2024 Oct 06; 21(5):264-281. PubMed ID: 39120667
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pre-exposure prophylaxis initiation and adherence among Black men who have sex with men (MSM) in three US cities: results from the HPTN 073 study.
    Wheeler DP, Fields SD, Beauchamp G, Chen YQ, Emel LM, Hightow-Weidman L, Hucks-Ortiz C, Kuo I, Lucas J, Magnus M, Mayer KH, Nelson LE, Hendrix CW, Piwowar-Manning E, Shoptaw S, Watkins P, Watson CC, Wilton L.
    J Int AIDS Soc; 2019 Feb 06; 22(2):e25223. PubMed ID: 30768776
    [Abstract] [Full Text] [Related]

  • 14. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project.
    Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, Matheson T, Trainor N, Blue RW, Estrada Y, Coleman ME, Elion R, Castro JG, Chege W, Philip SS, Buchbinder S, Kolber MA, Liu AY.
    J Acquir Immune Defic Syndr; 2015 Apr 01; 68(4):439-48. PubMed ID: 25501614
    [Abstract] [Full Text] [Related]

  • 15. Factors associated with long-term HIV pre-exposure prophylaxis engagement and adherence among transgender women in Brazil, Mexico and Peru: results from the ImPrEP study.
    Konda KA, Torres TS, Mariño G, Ramos A, Moreira RI, Leite IC, Cunha M, Jalil EM, Hoagland B, Guanira JV, Benedetti M, Pimenta C, Vermandere H, Bautista-Arredondo S, Vega-Ramirez H, Veloso VG, Caceres CF, Grinsztejn B, ImPrEP Study Group.
    J Int AIDS Soc; 2022 Oct 01; 25 Suppl 5(Suppl 5):e25974. PubMed ID: 36225148
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.
    Psaros C, Goodman GR, Lee JS, Rice W, Kelley CF, Oyedele T, Coelho LE, Phanuphak N, Singh Y, Middelkoop K, Griffith S, McCauley M, Rooney J, Rinehart AR, Clark J, Go V, Sugarman J, Fields SD, Adeyeye A, Grinsztejn B, Landovitz RJ, Safren SA, HPTN 083‐02 Study Team.
    J Int AIDS Soc; 2024 May 01; 27(5):e26252. PubMed ID: 38783534
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
    Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, Harris DR, Mulligan K, Zimet G, Mayer KH, Anderson P, Kiser JJ, Lally M, Brothers J, Bojan K, Rooney J, Wilson CM.
    JAMA Pediatr; 2017 Nov 01; 171(11):1063-1071. PubMed ID: 28873128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.